Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markman

Showing results (11-20 of 1,622) with videos related to

Pageof 163
Sort By:
The Oncologist|January 1, 1996
Intraperitoneal Therapy of Ovarian CancerMarkman
The Oncologist|January 1, 1997
The Role of CA-125 in the Management of Ovarian CancerMarkman
Current Oncology Reports|August 5, 2003
Randomized trials in oncology: a fertile ground for controversyMaurie Markman
Cancer|October 7, 2010
The relevant distinction between "progression" in ovarian cancer drug trials and the clinical decision to change therapyMaurie Markman
Oncology|November 6, 2010
A critical need to reconsider cancer trial eligibility requirementsMaurie Markman
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1990
Supportive careM Markman
Current Oncology Reports|August 17, 2010
Maintenance chemotherapy: an evolving and increasingly acceptable strategy in cancer managementMaurie Markman
British Medical Journal|August 27, 2010
Destruction that wasteth at noondayP Markman
Cancer Investigation|January 23, 2009
The myth of measurable disease in ovarian cancer: revisitedMaurie Markman
Oncology|March 25, 2011
Proposal to rigorously evaluate the clinical benefits associated with a novel anti-neoplastic strategy outside the confines of a randomized trialMaurie Markman
Pageof 163

Showing results (11-20 of 1,622) with videos related to

Sort By:
Pageof 163
The Oncologist|January 1, 1996
Intraperitoneal Therapy of Ovarian CancerMarkman
The Oncologist|January 1, 1997
The Role of CA-125 in the Management of Ovarian CancerMarkman
Current Oncology Reports|August 5, 2003
Randomized trials in oncology: a fertile ground for controversyMaurie Markman
Cancer|October 7, 2010
The relevant distinction between "progression" in ovarian cancer drug trials and the clinical decision to change therapyMaurie Markman
Oncology|November 6, 2010
A critical need to reconsider cancer trial eligibility requirementsMaurie Markman
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1990
Supportive careM Markman
Current Oncology Reports|August 17, 2010
Maintenance chemotherapy: an evolving and increasingly acceptable strategy in cancer managementMaurie Markman
British Medical Journal|August 27, 2010
Destruction that wasteth at noondayP Markman
Cancer Investigation|January 23, 2009
The myth of measurable disease in ovarian cancer: revisitedMaurie Markman
Oncology|March 25, 2011
Proposal to rigorously evaluate the clinical benefits associated with a novel anti-neoplastic strategy outside the confines of a randomized trialMaurie Markman
Pageof 163